DS
TPST icon

DRW Securities’s Tempest Therapeutics TPST Stock Holding History

DRW Securities’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,447
Closed -$30K – 1717
2025
Q4 		$30K Sell
10,447
-8,381
-45% -$59.3K ﹤0.01% 1151
2025
Q3 		$194K Buy
+18,828
New +$163K ﹤0.01% 1093

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DRW Securities's TPST Position: Q1 2026 in Review

DRW Securities sold out of Tempest Therapeutics (TPST) in Q1 2026, closing a stake of 10,447 shares — an estimated $30K sold.

DRW Securities first reported a position in TPST in Q3 2025 and held it in 2 quarters. The position peaked at $194K in Q3 2025. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • DRW Securities reported no remaining Tempest Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 10,447 Tempest Therapeutics shares in Q1 2026, an estimated $30K.
  • DRW Securities first reported a position in Tempest Therapeutics in Q3 2025 and held it in 2 quarters.
  • DRW Securities's Tempest Therapeutics position peaked at $194K in Q3 2025.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.